Evaluation of a novel stent technology: the Genous EPC capturing stent

Evaluation of a novel stent technology: the Genous EPC capturing stent

Authors	M. Klomp
Supervisors	R.J. de Winter C.J.M. de Vries
Cosupervisors	J.G.P. Tijssen
Award date	20-01-2012
ISBN	9789461911162
Number of pages	331
Organisations	Faculty of Medicine (AMC-UvA)
Abstract	Tegenwoordig gebruiken ziekenhuizen een nieuwe stent bij dotterbehandelingen van kransslagadervernauwingen. Deze Genous-stent heeft een laag met antistoffen waardoor het behandelde bloedvat snel bedekt raakt met lichaamseigen cellen. Zo wordt tegengegaan dat er opnieuw een vernauwing optreedt of dat er zich stolsels gaan vormen. Voordeel is dat patiënten maar kort antistollingsmedicijnen nodig hebben. Uit het onderzoek van Margo Klomp blijkt dat patiënten met diabetes, ouderen en patiënten met gevorkte vernauwingen goed behandeld kunnen worden met de stent. Bij patiënten met complex vaatlijden lijkt de stent over een periode van twaalf maanden minder effectief dan medicijnafgevende stents, maar er is langere follow-up nodig voor een goede vergelijking.
Document type	PhD thesis
Note	Research conducted at: Universiteit van Amsterdam
Language	English
Downloads	Front cover Title pages Contents 2.1: Design and rationale of the TRI-stent Adjudication Study (TRIAS) program 2.2: Endothelial progenitor cell capturing stent versus the paclitaxel-eluting stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: the randomized, single center TRIAS pilot study 2.3: Two-year follow-up of the Genous endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary lesions with a high risk of coronary restenosis: a randomized, single-center, pilot study 2.4: One-year outcome of the TRIAS high risk of restenosis study; a multi-center, randomized trial comparing Genous EPC capturing stents with drug-eluting stents 3.1: One-year clinical outcome in an unselected patient population treated with the Genous endothelial progenitor cell capturing stent 3.2: Three-year clinical follow-up of an unselected patient population treated with the Genous endothelial progenitor cell capturing stent 4.2: Twelve-month outcomes after coronary stenting with the Genous Bio-engineered R stent in diabetic patients from the e-HEALING registry 4.4: Differences in cardiovascular risk factors and clinical outcomes between West-European and Asian patients treated with the Genous Bio-engineered R stent: a sub-study of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry 4.5: Duration of dual antiplatelet therapy after coronary stenting with the Genous Bio-engineered R stent in patients from the e-HEALING registry 4.6: Applying the National Institute for Clinical Excellence criteria to patients treated with the Genous Bio-engineered R stent: a sub-study of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry 5.1: One-year clinical outcome after provisional T-stenting with the endothelial progenitor cell capturing stent for bifurcation lesions 5.2: Twelve-month clinical outcomes after coronary stenting with the Genous Bio-engineered R stent in patients with a bifurcation lesion from the e-HEALING registry 6.1: Understanding the role of endothelial progenitor cells in cardiovascular disease, coronary artery lesion progression, and in-stent restenosis 6.2: The relationship between the number of pre-procedural circulating endothelial progenitor cells and angiographic restenosis following coronary artery stent placement 7.1: Significant intimal hyperplasia regression from 6 to 18 month follow-up after stenting with a Genous endothelial progenitor cell capturing stent 8: Summary, conclusions and future perspectives 9: Acknowledgments Curriculum vitae
Permalink to this page

Back

UvA-DARE

Digital Academic Repository

Evaluation of a novel stent technology: the Genous EPC capturing stent